CSBRHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 3 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Champions Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (79): Smaller than most of the companies we track.
Momentum (16): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CSBR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Mar 2025 | Craig-Hallum | Maintains | Buy | $8.00 → $12 |
| 12 Dec 2024 | Craig-Hallum | Maintains | Buy | — |
| 12 Sept 2024 | Craig-Hallum | Upgrade | Buy | — |
| 13 Mar 2024 | Craig-Hallum | Downgrade | Hold | — |
| 22 Sept 2023 | Roth MKM | Maintains | Buy | — |
| 15 Mar 2021 | Roth Capital | Maintains | Buy | — |
| 18 Nov 2019 | Benchmark | Initiates | Speculative Buy | — |
| 20 Sept 2019 | Roth Capital | Initiates | Buy | — |
| 24 July 2019 | Janney Capital | Downgrade | Neutral | — |
| 24 July 2019 | Janney Montgomery Scott | Downgrade | Neutral | — |
| 17 July 2018 | Craig-Hallum | Initiates | Buy | — |
| 15 May 2018 | Dawson James | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CSBR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, Champions Oncology, Inc. returned −21.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 65% of US stocks
Cheaper than 5% of US stocks
Cheaper than 1% of US stocks
Higher than 49% of US stocks
Higher than 50% of US stocks
Higher than 63% of US stocks
Higher than 29% of US stocks
Higher than 28% of US stocks
Higher than 28% of US stocks
Higher than 37% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Champions Oncology, Inc. has a market value of $68.8M and an enterprise value of $75.9M.
Revenue in the twelve months to 30 Apr 2026: $59.4M. The latest quarter grew 8.8% year on year.
Net income over the same four quarters: −$1.1M, a −1.9% net margin.
Free cash flow in the twelve months to 30 Apr 2026: −$5.0M.
Trailing P/E: 35.9×; forward P/E: 49.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Champions Oncology, Inc. employs 214 people — $278K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Champions Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Champions Oncology reported first-quarter fiscal 2027 results with revenue and margin growth, stronger adjusted earnings, and surging data-license revenues, though its stock slipped following the earnings release.
Why it matters — The report highlights continued growth in core revenue, margins, adjusted earnings, and data-license revenue despite the stock's post-earnings decline.
Champions Oncology, Inc. held its Q1 2027 earnings call, and the full transcript of the call was published by Seeking Alpha. The item consists of the headline and transcript availability, with no financial details or management commentary included.
Why it matters — A CSBR watcher would care because the Q1 2027 earnings call transcript is now available as a primary source for reviewing the company's latest quarterly performance and management remarks.
Champions Oncology reported first-quarter fiscal 2027 results featuring revenue growth, improved margins, and its fifth consecutive quarter of positive adjusted EBITDA. Both its translational oncology services and data licensing businesses contributed to the quarterly performance.
Why it matters — CSBR watchers would note the sustained revenue growth and improving profitability across its core business segments as a sign of continuing financial momentum.
Champions Oncology reported first-quarter fiscal 2027 financial results, with revenue of $15.2 million, an 8.8% increase year over year. The company also reported an improved oncology services margin of 51% (up from 43%) and adjusted EBITDA of $671,000, up from $59,000 in the prior-year period.
Why it matters — CSBR watchers would note the company delivered year-over-year revenue growth alongside a material improvement in oncology services margins and adjusted EBITDA, reflecting better study execution and conversion in its core research services business.
Champions Oncology reported fourth-quarter fiscal 2026 growth with revenue gains, margin improvement, and progress from operational initiatives, though CSBR stock dipped following the earnings announcement.
Why it matters — For CSBR watchers, the results show record revenue growth and operational progress even as the market reacted negatively in the short term.
Of the 1 analysts covering Champions Oncology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Champions Oncology, Inc. 28 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, Champions Oncology, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).
No analyst covering Champions Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSBR are extrapolating price history, which says nothing about the business.
Champions Oncology, Inc. returned -21.1% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development.
The most recent item we track (Zacks Investment Research, 15 Sept 2026): "CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth". Champions Oncology reported first-quarter fiscal 2027 results with revenue and margin growth, stronger adjusted earnings, and surging data-license revenues, though its stock slipped following the earnings release.
Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies. Its core offerings include proprietary tumor models, in vivo and ex vivo research platforms, biomarker analysis, and the TumorGraft technology platform, which supports more personalized approaches to oncology research. The company also offers Lumin Bioinformatics, a software platform that combines research and clinical data for computational cancer analysis and decision-making support. Champions Oncology serves drug developers, research organizations, and medical professionals through technology-enabled services centered on improving the understanding and development of cancer treatments. Headquartered in Hackensack, New Jersey, Champions Oncology operates as a specialized provider within the broader oncology contract research and life sciences tools market.
CEO Mr. Robert Brainin · 214 employees · United States · https://www.championsoncology.com
